Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tadios
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tadios is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 23, 2022
Lead Product(s) : Tadios
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Engensis
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Engensis is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Engensis
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Engensis is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 04, 2022
Details : Engensis is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Neuropathies.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 05, 2021
Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis
Details : Engensis is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 17, 2020
Lead Product(s) : Donaperminogene Seltoplasmid
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1/2a Trial of Gene Therapy Engensis for CMT1A Begins in Korea
Details : The trial aims to evaluate Engensis’ safety and tolerability by administering the treatment to the leg of twelve CMT1A patients in Korea.
Product Name : Engensis
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Donaperminogene Seltoplasmid
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy
Details : Engensis is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Neuropathies.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 14, 2020